EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Coherus Oncology's Enterprise Value is $103.56 Mil.
Coherus Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-170.57 Mil. Therefore, Coherus Oncology's EV-to-FCF for today is -0.61.
The historical rank and industry rank for Coherus Oncology's EV-to-FCF or its related term are showing as below:
CHRS'
s EV-to-FCF Range Over the Past 10 Years
Min: -43.43 Med: -3.32 Max: 634.55
Current: -0.61
During the past 13 years, the highest EV-to-FCF of Coherus Oncology was 634.55. The lowest was -43.43. And the median was -3.32.
CHRS's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs CHRS: -0.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Coherus Oncology's PE Ratio (TTM) for today is calculated as:
Coherus Oncology's share price for today is $1.495.
Coherus Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.670.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Coherus Oncology EV-to-FCF Related Terms
Coherus Oncology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Coherus Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's EV-to-FCF falls into.
Coherus Oncology's current Enterprise Value is $103.56 Mil.
Coherus Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-170.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (CHRS) has a EV-to-FCF of -0.61 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #999999 out of 333 companies in the Biotechnology industry.
Is Coherus Oncology's EV-to-FCF too high?
Coherus Oncology's current EV-to-FCF is -0.61. Based on the distribution chart, Coherus Oncology ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's EV-to-FCF compare to CNXU and LENZ?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #999999 out of 333 companies for EV-to-FCF. This places Coherus Oncology in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current EV-to-FCF is -0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (CHRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.77, compared to a current price of $1.50 — trading 94.2% above its estimated fair value. The current EV-to-FCF is -0.61. Coherus Oncology's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Coherus Oncology (CHRS), the current EV-to-FCF is -0.61 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (CHRS) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of $1.50 is trading 94.2% above its estimated GF Value™ of $0.77.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for CHRS:
EV-to-FCF: -0.61
GF Value™: $0.77 vs. price of $1.50 (94.2% above fair value)
No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score
Get the complete analysis for CHRS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHRS has been successfully added to your 
